Atopic dermatitis (eczema): open trials in Argentina

3 open trials have a site in Argentina. Registry data; only the trial team decides who can take part.

NCT05735483
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Trial Treatment · Phase 3 · Eli Lilly and Company
Fundacion Cidea, Buenos Aires · Fundacion Respirar, Buenos Aires · CONEXA Investigacion Clinica S.A., Buenos Aires · Psoriahue, Ciudad Autonoma de Buenos Aire · Instituto de Neumonología Y Dermatología, Ciudad Autonoma de Buenos Aire · Centro de Investigaciones Metabólicas (CINME), Ciudad Autónoma de Buenos Aires · Fundacion Estudios Clinicos, Rosario
Registry updated 2026-10-26
NCT06947993
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Trial Treatment · Phase 2 · Novartis Pharmaceuticals
CABA · Rosario
Registry updated 2026-09-28
NCT05575882
Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream for Very Dry, Irritated to Atopic Sensitive Skin.
Trial Treatment · NAOS Argentina S.A.
Cirec Latam, Ciudad Autónoma de Buenos Aire
Registry updated 2025-03-25

This page is not medical advice. Talk to your doctor before contacting a trial.

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis